Related Experiment Video

Updated: Jul 7, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Free p-cresol is associated with cardiovascular disease in hemodialysis patients

B K I Meijers1, B Bammens, B De Moor

  • 1Division of Nephrology, Department of Medicine, University Hospital Leuven, Leuven, Belgium.

Kidney International
|February 29, 2008
PubMed

Insights

Free p-cresol, a uremic toxin, is a significant cardiovascular disease risk factor in non-diabetic hemodialysis patients. This finding highlights a novel link between kidney disease and heart health.

Area of Science:

  • Nephrology
  • Cardiology
  • Toxicology

Background:

  • Cardiovascular disease (CVD) is a major complication in chronic kidney disease (CKD).
  • Uremic retention solutes, like p-cresol, are suspected contributors to CVD risk in CKD.
  • Traditional and novel cardiovascular risk factors require further investigation in CKD populations.

Purpose of the Study:

  • To investigate the association between free serum p-cresol concentrations and CVD risk.
  • To compare the strength of p-cresol's association with CVD relative to other risk factors.
  • To determine if p-cresol is a novel cardiovascular risk factor in hemodialysis patients.

Main Methods:

  • Utilized univariate and multivariate Cox proportional hazard analyses.
  • Assessed the time to the first cardiovascular event as the primary endpoint.
  • Analyzed free serum p-cresol concentrations in relation to CVD outcomes.

Main Results:

  • Univariate analysis revealed a significant association between free p-cresol and CVD events.
  • Multivariate analysis confirmed free p-cresol as a significant CVD risk factor in non-diabetic patients.
  • No significant relationship was found between p-cresol and CVD in diabetic patients, despite higher levels.

Conclusions:

  • Free p-cresol is identified as a novel cardiovascular risk factor in non-diabetic hemodialysis patients.
  • The association between p-cresol and CVD may differ between diabetic and non-diabetic individuals with CKD.
  • Further research is warranted to elucidate the mechanisms linking p-cresol to cardiovascular events in CKD.

Related Concept Videos

Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration01:25

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...